Apimeds Pharmaceuticals US, Inc. (APUS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
APUS currently has 15.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 976.97% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 26, 2026 |
10-Q filing | 15.5M shares outstanding |
16M | 0 |
| May 04, 2026 |
10-K filing | 12.6M shares outstanding |
13M | 0 |
| Mar 26, 2026 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 12,575,983 → 1,257,598 |
1.3M | 0 |
| Dec 02, 2025 |
8-K filing: Apimeds Pharmaceuticals US, Inc. enters into a merger agreement with MindWave Innovations Inc, which includes a reverse stock split of the Acquiror Common Stock at a ratio of 1-for-10 and the issuance of senior convertible notes in an aggregate principal amount of up to $120,900,000 at an 8% original issue discount. |
13M | 0 |
| Nov 12, 2025 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| Aug 19, 2025 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| May 20, 2025 |
10-Q filing | 11.6M shares outstanding |
12M | 0 |
| May 12, 2025 |
8-K filing: Apimeds Pharmaceuticals US, Inc. consummated its initial public offering (IPO) of 3,375,000 shares of common stock at $4.00 per share, generating gross proceeds of $13.5 million, and also issued 297,133 shares of common stock upon conversion of convertible promissory notes at $2.60 per share. ($13.5M proceeds) |
8.2M | 0 |
| May 02, 2025 |
POS AM filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 0 |
| May 01, 2025 |
POS AM filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 0 |
| Apr 17, 2025 |
POS AM filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 0 |
| Apr 15, 2025 |
10-K filing | 7.9M shares outstanding |
7.9M | 4.7M |
| Feb 10, 2025 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 4.7M |
| Feb 06, 2025 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 5.2M |
| Jan 29, 2025 |
S-1/A filing: This S-1/A filing is for a firm commitment initial public offering of 4,500,000 shares of common stock of Apimeds Pharmaceuticals US, Inc., with an anticipated IPO price between $4.00 and $5.00, and an over-allotment option for an additional 675,000 shares. |
8.2M | 5.2M |
| Jan 10, 2025 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 3.8M |
| Dec 20, 2024 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 4.3M |
| Dec 09, 2024 |
S-1/A filing: Apimeds Pharmaceuticals US, Inc. is conducting a firm commitment initial public offering of common stock, with an anticipated initial public offering price between $3.00 and $4.00 per share, seeking to list its common stock on The New York Stock Exchange American under the symbol "APUS." |
8.2M | 3.5M |
| Nov 08, 2024 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. |
8.2M | 3.5M |
| Sep 25, 2024 |
S-1 filing: Apimeds Pharmaceuticals US, Inc. is conducting a firm commitment initial public offering of shares of common stock, with the intention to list on The New York Stock Exchange American under the symbol 'APUS'. |
21M | 0 |